|
|
|
|
LEADER |
02963nam a2200469 4500 |
001 |
978-3-319-94827-0 |
003 |
DE-He213 |
005 |
20191220130317.0 |
007 |
cr nn 008mamaa |
008 |
181115s2019 gw | s |||| 0|eng d |
020 |
|
|
|a 9783319948270
|9 978-3-319-94827-0
|
024 |
7 |
|
|a 10.1007/978-3-319-94827-0
|2 doi
|
040 |
|
|
|d GrThAP
|
050 |
|
4 |
|a RB45
|
072 |
|
7 |
|a MJF
|2 bicssc
|
072 |
|
7 |
|a MED038000
|2 bisacsh
|
072 |
|
7 |
|a MJF
|2 thema
|
082 |
0 |
4 |
|a 616.15
|2 23
|
245 |
1 |
0 |
|a Minimal Residual Disease Testing
|h [electronic resource] :
|b Current Innovations and Future Directions /
|c edited by Todd E. Druley.
|
250 |
|
|
|a 1st ed. 2019.
|
264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2019.
|
300 |
|
|
|a VIII, 197 p. 28 illus., 27 illus. in color.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
505 |
0 |
|
|a Introduction -- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma -- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies -- Monitoring AML Response Using "Difference From Normal" Flow Cytometry -- ML-DS: A Unique Condition for Measurable Residual Disease Detection -- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.
|
520 |
|
|
|a This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice.
|
650 |
|
0 |
|a Hematology.
|
650 |
|
0 |
|a Oncology .
|
650 |
|
0 |
|a Pathology.
|
650 |
1 |
4 |
|a Hematology.
|0 http://scigraph.springernature.com/things/product-market-codes/H3307X
|
650 |
2 |
4 |
|a Oncology.
|0 http://scigraph.springernature.com/things/product-market-codes/H33160
|
650 |
2 |
4 |
|a Pathology.
|0 http://scigraph.springernature.com/things/product-market-codes/H4800X
|
700 |
1 |
|
|a Druley, Todd E.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319948263
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319948287
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-94827-0
|z Full Text via HEAL-Link
|
912 |
|
|
|a ZDB-2-SME
|
950 |
|
|
|a Medicine (Springer-11650)
|